Table 2. Adverse events.

Events	0–30 days (n=50)	>30 days (n=41)
Death	7 (14.0)	4 (9.8)
Cardiovascular	7 (14.0)	4 (9.8)
Non-cardiovascular	0 (0.0)	0 (0.0)
Stroke	2 (4.0)	0 (0.0)
Disabling stroke	0 (0.0)	0 (0.0)
Non-disabling stroke	2 (4.0)	1 (2.4)
Myocardial infarction	0 (0.0)	0 (0.0)
Acute renal impairment, stage 3	5 (10.0)	0 (0.0)
Major vascular complications	0 (0.0)	0 (0.0)
Major cardiac structural complication	2 (4.0)	0 (0.0)
Major bleeding	9 (18.0)	0 (0.0)
Reoperation for any reason	5 (10.0)	1 (2.4)†
Reoperation for bleeding	5 (10.0)	0 (0.0)
Reoperation for other*	0 (0.0)	1 (2.4)†
New-onset atrial fibrillation	7 (14.0)	2 (4.9)
Hemolysis	0 (0.0)	0 (0.0)
Endocarditis†	1 (2.0)	1 (2.4)
Device embolization	0 (0.0)	0 (0.0)
Device thrombosis	0 (0.0)	0 (0.0)
Cardiovascular re-hospitalization	8 (16.0)	13 (31.7)
Re-hospitalization for heart failure	4 (8.0)	8 (19.5)

Data are presented as n (%). *, reoperation for wound infection at incision site; ^†, the endocarditis event was related to placement of a pacemaker lead.